How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Description:
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Sponsor:
OranomedContacts:
Jason D Hurt, MDjason.hurt@oranomed.com
4696380744
Government Study Link:
NCT05283330 - Click here to see study onClinicalTrials.gov
²¹²Pb-DOTAM-GRPR1
Isotope(s):
Target(s):
- GRPR
Chelator: DOTAM
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Not yet provided. Contact Jason D Hurt, MD for more information.
4696380744
jason.hurt@oranomed.com
